News articles about iShares NASDAQ Biotechnology Index (NASDAQ:IBB) have been trending positive this week, Accern reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. iShares NASDAQ Biotechnology Index earned a news sentiment score of 0.35 on Accern’s scale. Accern also assigned media stories about the financial services provider an impact score of 45.6718266689303 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news articles that may have impacted Accern Sentiment’s rankings:
- Oak Grove Capital LLC Buys New Position in iShares NASDAQ Biotechnology Index (IBB) (americanbankingnews.com)
- Private Management Group Inc. Buys 56,627 Shares of iShares NASDAQ Biotechnology Index (IBB) (americanbankingnews.com)
- ETF Preview: ETFs, Futures Point Lower as Fed Meeting Minutes Indicate Likelihood of More Interest Rate Hikes – Nasdaq (nasdaq.com)
- Mid-Day ETF Update: ETFs, Stocks Extend Gains on Fed Speak and Pull Back in Treasury Yields – Nasdaq (nasdaq.com)
- Mid-Day ETF Update: ETFs, Stocks Higher as Street Shrugs Off Concerns for Possible Fed Interest Rate Hikes – Nasdaq (nasdaq.com)
iShares NASDAQ Biotechnology Index (NASDAQ IBB) traded up $0.81 on Monday, reaching $111.49. The company’s stock had a trading volume of 2,017,012 shares, compared to its average volume of 3,270,000. The firm has a market capitalization of $9,710.00, a price-to-earnings ratio of 3.68 and a beta of 1.37. iShares NASDAQ Biotechnology Index has a 52 week low of $94.20 and a 52 week high of $119.30.
TRADEMARK VIOLATION NOTICE: “iShares NASDAQ Biotechnology Index (IBB) Receives Daily Coverage Optimism Score of 0.35” was published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3224305/ishares-nasdaq-biotechnology-index-ibb-receives-daily-coverage-optimism-score-of-0-35.html.
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Receive News & Ratings for iShares NASDAQ Biotechnology Index Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares NASDAQ Biotechnology Index and related companies with MarketBeat.com's FREE daily email newsletter.